Market Overview:
The global genital herpes treatment drugs market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of genital herpes, rising awareness about available treatments, and growing demand for better-tolerated therapies. Based on type, the global genital herpes treatment drugs market is segmented into acyclovir, famciclovir, and valacyclovir. Acyclovir is currently the most commonly prescribed drug for treating genital herpes infections and held a dominant share of the global market in 2017. However, over-the-counter availability of generic versions of acyclovir has led to its declining popularity in recent years. Famciclovir and valacyclovir are second-generation antiviral agents that are becoming increasingly popular due to their better tolerability profiles as compared with acyclovir. Based on application, hospitals accounted for the majority share of the global genital herpes treatment drugs market in 2017; however, clinics are expected to witness faster growth during the forecast period owing to their lower costs as compared with hospitals.
Product Definition:
There are a few different drugs that are used to treat genital herpes. Acyclovir (Zovirax), famciclovir (Famvir), and valacyclovir (Valtrex) are all antiviral drugs that work by stopping the herpes virus from multiplying. They can help shorten the length of an outbreak, make it less severe, and help prevent future outbreaks.
Acyclovir:
Acyclovir is a medication used for the treatment of genital herpes simplex virus infections. It’s approved by FDA to treat recurrent attacks of HSV 1 and 2, but it can also be used to reduce the frequency of future outbreaks if taken consistently. Acyclovir is an antiviral drug that works by decreasing viral replication in the host cell.
Famciclovir:
Famciclovir is a drug used for the treatment of genital herpes simplex virus 2 and 3 (HSV-2, HSV-3). It works by decreasing the ability of the infected cells to multiply. This medication is approved by both U.S. FDA (Food and Drug Administration) and EMA (European Medicines Agency).
Application Insights:
Based on application, the global genital herpes treatment drugs market is segmented into hospitals, clinics and others. Hospitals held the largest share in 2017 owing to factors such as a large patient base with diagnosed cases of Genital Herpes infection and presence of specialized healthcare facilities for treating GVHD. Moreover, hospitals are considered to be one of the highest revenue-generating centers for pharmaceutical companies manufacturing these medicines due to its high demand and prevalence rate.
Clinic was the second-largest segment in 2017 owing to increasing awareness about diagnosis & treatment options among general practitioners (GPs). A rising number of clinics offering Genital Herpes Treatment Drug (acyclovir or famciclovir) as an outpatient service is also expected to boost industry growth over the forecast period. Furthermore, growing penetration by antiviral medication in primary care settings will further propel demand over next few years.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of manufacturers and suppliers, high awareness levels about available treatment options, and availability of well-developed healthcare infrastructure are some factors attributing to its largest share. Moreover, introduction of novel drugs with improved efficacy is expected to drive regional growth over the forecast period.
Asia Pacific is estimated to witness lucrative CAGR during the forecast period owing to increasing prevalence rates coupled with rising disposable income in emerging economies such as India and China. Furthermore, government initiatives for creating awareness about genital herpes are anticipated to fuel market growth during the forecast period.
Growth Factors:
- Increasing incidence of genital herpes infections
- Growing awareness about the disease and its treatment options
- Rising demand for effective and safe drugs for the treatment of genital herpes infections
- Technological advancements in drug development and delivery systems
- Availability of government funding for research on new drugs for the treatment of genital herpes
Scope Of The Report
Report Attributes
Report Details
Report Title
Genital Herpes Treatment Drugs Market Research Report
By Type
Acyclovir, Famciclovir, Valacyclovir
By Application
Hospitals, Clinic, Others
By Companies
AstraZeneca, Plc., Apotheca, Inc., Asahi Kasei Pharma Corporation, Carlsbad Technology, Inc., GlaxoSmithkline, Plc., Mylan N.V., Novartis AG., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Zydus Pharmaceuticals, Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
126
Number of Tables & Figures
89
Customization Available
Yes, the report can be customized as per your need.
Global Genital Herpes Treatment Drugs Market Report Segments:
The global Genital Herpes Treatment Drugs market is segmented on the basis of:
Types
Acyclovir, Famciclovir, Valacyclovir
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AstraZeneca, Plc.
- Apotheca, Inc.
- Asahi Kasei Pharma Corporation
- Carlsbad Technology, Inc.
- GlaxoSmithkline, Plc.
- Mylan N.V.
- Novartis AG.
- Merck & Co., Inc.
- Teva Pharmaceutical Industries Ltd.
- Zydus Pharmaceuticals, Inc.
Highlights of The Genital Herpes Treatment Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Acyclovir
- Famciclovir
- Valacyclovir
- By Application:
- Hospitals
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Genital Herpes Treatment Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There are many different types of treatment drugs for genital herpes. These drugs can help to relieve the symptoms of the virus, prevent new outbreaks, and sometimes cure the infection. Some common treatment drugs include antiviral medications such as acyclovir (Zovirax), famciclovir (Famvir), and valacyclovir (Valtrex). Other treatments may include topical creams or gels that are applied to the skin directly, oral medication taken by mouth, or a combination of these approaches. Treatment options vary depending on which type of herpes virus is causing an outbreak and what works best for individual patients.
Some of the major players in the genital herpes treatment drugs market are AstraZeneca, Plc., Apotheca, Inc., Asahi Kasei Pharma Corporation, Carlsbad Technology, Inc., GlaxoSmithkline, Plc., Mylan N.V., Novartis AG., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Zydus Pharmaceuticals, Inc..
The genital herpes treatment drugs market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Genital Herpes Treatment Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Genital Herpes Treatment Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Genital Herpes Treatment Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Genital Herpes Treatment Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Genital Herpes Treatment Drugs Market Size & Forecast, 2018-2028
4.5.1 Genital Herpes Treatment Drugs Market Size and Y-o-Y Growth
4.5.2 Genital Herpes Treatment Drugs Market Absolute $ Opportunity
Chapter 5 Global Genital Herpes Treatment Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Genital Herpes Treatment Drugs Market Size Forecast by Type
5.2.1 Acyclovir
5.2.2 Famciclovir
5.2.3 Valacyclovir
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Genital Herpes Treatment Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Genital Herpes Treatment Drugs Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Genital Herpes Treatment Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Genital Herpes Treatment Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Genital Herpes Treatment Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Genital Herpes Treatment Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Genital Herpes Treatment Drugs Market Size Forecast by Type
9.6.1 Acyclovir
9.6.2 Famciclovir
9.6.3 Valacyclovir
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Genital Herpes Treatment Drugs Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Genital Herpes Treatment Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Genital Herpes Treatment Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Genital Herpes Treatment Drugs Market Size Forecast by Type
10.6.1 Acyclovir
10.6.2 Famciclovir
10.6.3 Valacyclovir
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Genital Herpes Treatment Drugs Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Genital Herpes Treatment Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Genital Herpes Treatment Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Genital Herpes Treatment Drugs Market Size Forecast by Type
11.6.1 Acyclovir
11.6.2 Famciclovir
11.6.3 Valacyclovir
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Genital Herpes Treatment Drugs Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Genital Herpes Treatment Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Genital Herpes Treatment Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Genital Herpes Treatment Drugs Market Size Forecast by Type
12.6.1 Acyclovir
12.6.2 Famciclovir
12.6.3 Valacyclovir
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Genital Herpes Treatment Drugs Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Genital Herpes Treatment Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Genital Herpes Treatment Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Genital Herpes Treatment Drugs Market Size Forecast by Type
13.6.1 Acyclovir
13.6.2 Famciclovir
13.6.3 Valacyclovir
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Genital Herpes Treatment Drugs Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Genital Herpes Treatment Drugs Market: Competitive Dashboard
14.2 Global Genital Herpes Treatment Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AstraZeneca, Plc.
14.3.2 Apotheca, Inc.
14.3.3 Asahi Kasei Pharma Corporation
14.3.4 Carlsbad Technology, Inc.
14.3.5 GlaxoSmithkline, Plc.
14.3.6 Mylan N.V.
14.3.7 Novartis AG.
14.3.8 Merck & Co., Inc.
14.3.9 Teva Pharmaceutical Industries Ltd.
14.3.10 Zydus Pharmaceuticals, Inc.
